We are live on ! Find out more
ASMB icon

Assembly Biosciences
ASMB

65 hedge funds and large institutions have $259M invested in Assembly Biosciences in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,736% more call options, than puts

Call options by funds: $4.16M | Put options by funds: $86K

133% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 12

33% more funds holding

Funds holding: 49 → 65 (+16)

0.28% more ownership

Funds ownership: 5.75% → 6.03% (+0.28%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

14% less capital invested

Capital invested by funds: $301M → $259M (-$42.8M)

18% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 17

Holders
65
Holders Change
+16
Holders Change %
+32.65%
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
28
Increased
14
Reduced
17
Closed
12
Calls
$4.16M
Puts
$86K
Net Calls
+$4.07M
Net Calls Change
+$648K

Top Buyers

1
BlackRock
BlackRock
New York
+$12.9M
2
State Street
State Street
Massachusetts
+$4.81M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.89M
4
Northern Trust
Northern Trust
Illinois
+$3.16M
5
Renaissance Technologies
Renaissance Technologies
New York
+$3.15M

Top Sellers

1
O
OrbiMed
New York
-$8.66M
2
QF
QVT Financial
New York
-$7.1M
3
PA
Perceptive Advisors
New York
-$5.22M
4
Millennium Management
Millennium Management
New York
-$2.54M
5
ACA
Avoro Capital Advisors
New York
-$2.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
1
EcoR1 Capital
California
$60.8M – – –
Jennison Associates
2
Jennison Associates
New York
$40.3M -$1.46M -5,178 -3%
ACP
3
Acuta Capital Partners
California
$21.3M -$1.64M -5,828 -6%
O
4
OrbiMed
New York
$18.3M -$8.66M -30,739 -29%
BlackRock
5
BlackRock
New York
$18M +$12.9M +45,952 +171%
Vanguard Group
6
Vanguard Group
Pennsylvania
$12.6M +$2.51M +8,922 +21%
ACA
7
Avoro Capital Advisors
New York
$12.5M -$2.09M -7,437 -13%
PA
8
Perceptive Advisors
New York
$9.12M -$5.22M -18,544 -33%
RSCM
9
Rock Springs Capital Management
Maryland
$8.05M – – –
QF
10
QVT Financial
New York
$7.67M -$7.1M -25,194 -44%
BBA
11
Baker Bros. Advisors
New York
$5.16M – – –
State Street
12
State Street
Massachusetts
$4.23M +$4.81M +17,093 New
Northern Trust
13
Northern Trust
Illinois
$4.03M +$3.16M +11,210 +221%
JP Morgan Chase
14
JP Morgan Chase
New York
$3.43M +$3.89M +13,825 New
Millennium Management
15
Millennium Management
New York
$3.01M -$2.54M -9,005 -43%
Renaissance Technologies
16
Renaissance Technologies
New York
$2.97M +$3.15M +11,200 +1,414%
LSC
17
Lyon Street Capital
California
$2.81M +$2.49M +8,842 +353%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.54M +$590K +2,094 +26%
Axa
19
Axa
France
$2.48M +$2.81M +9,995 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$2.27M -$544K -1,933 -17%
Invesco
21
Invesco
Georgia
$1.32M +$1.5M +5,324 New
OAM
22
Oxford Asset Management
United Kingdom
$1.08M +$1.23M +4,359 New
Deutsche Bank
23
Deutsche Bank
Germany
$1.05M +$961K +3,414 +410%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$939K – – –
TCIM
25
TIAA CREF Investment Management
New York
$930K +$1.06M +3,754 New
1
2 3 4

ASMB Hedge Fund Activity: Q2 2017 in Review

65 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2017, worth a combined $259M — down 14% from $301M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ASMB positions and 12 closed out — a net gain of 16 holders — while 14 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was OrbiMed, cutting an estimated $8.66M.

  • 65 institutional investors held Assembly Biosciences (ASMB) as of Q2 2017, up from 49 in Q1 2017.
  • Funds reported $259M of Assembly Biosciences stock for Q2 2017, down 14% quarter-over-quarter.
  • 28 funds opened new Assembly Biosciences positions in Q2 2017 and 12 closed out, a net change of +16 holders.
  • The largest Assembly Biosciences buyer in Q2 2017 was BlackRock, an estimated $12.9M added.
  • The largest Assembly Biosciences seller in Q2 2017 was OrbiMed, an estimated $8.66M sold.

Based on aggregated 13F filings for Q2 2017.